

## We're changing how we manage Skyrizi SC and Stelara SC, starting Aug. 15

For dates of service on or after Aug. 15, 2022, Blue Cross Blue Shield of Michigan and Blue Care Network are changing how we manage the following medications for our Medicare Advantage members:

- Skyrizi<sup>®</sup> SC (risankizumab-rzaa), HCPCS code J3590
- Stelara<sup>®</sup> SC (ustekinumab), HCPCS code J3357

This change will apply to our Medicare Plus Blue and BCN Advantage members.

**Important:** This change doesn't affect Skyrizi IV, HCPCS code J3590, and Stelara IV, HCPCS code J3358, which will continue to be managed as part of members' Part B medical benefits.

### What will change on Aug. 15

For dates of service on or after Aug. 15, Medicare Plus Blue and BCN Advantage members who previously received Skyrizi SC or Stelara SC under the Part B medical benefit will be required to continue their treatment under their Part D pharmacy benefits.

We're making this change because these therapies can be safely and conveniently self-administered in the home; the Centers for Medicare and Medicaid Services, or CMS, has added these medications to the [Self-Administered Drug Exclusion List: \(SAD List\)\\*](#).

As a result:

- These drugs will no longer be covered when administered by a doctor or other health care professional under the Part B medical benefit.
- Skyrizi SC is not included in our Medicare Advantage Part D formularies, but providers can request prior authorization for it as an exception. (See "How to submit prior authorization requests for Skyrizi SC and Stelara SC".)

Note: Skyrizi IV will continue to require prior authorization through the Part B medical benefit, using the NovoLogix web tool.

- Stelara SC will be covered only through Medicare Advantage members' Part D prescription drug plans. Prior authorization will continue to be required through members' Part D benefits. (See "How to submit prior authorization requests for Skyrizi SC and Stelara SC".)

Note: Stelara IV will continue to require prior authorization through the Part B medical benefit, using the NovoLogix web tool.

- Your patients can obtain these medications at pharmacies that dispense specialty drugs. They can also obtain these drugs through an AllianceRx Walgreens Pharmacy.

Note: For members who don't have Part D pharmacy benefits through Blue Cross or BCN, providers need to work with the pharmacy vendor that provides each member's Part D coverage.

### How to submit prior authorization requests for Skyrizi SC and Stelara SC

For members who have Part D pharmacy benefits through Medicare Plus Blue or BCN Advantage, providers will need to submit prior authorization requests for Skyrizi SC and Stelara SC as follows:

- **Electronically:** Through CoverMyMeds<sup>®</sup> or another free ePA tool, such as Surescripts<sup>®</sup> or ExpressPAth<sup>®</sup>. See [Save time and submit your prior authorization requests electronically for pharmacy benefit drugs](#) (PDF) for more information.
- **By phone:** Call 1-800-437-3803 and follow the prompts for medications billed through the pharmacy benefit.
- **By fax:**
  - For Medicare Plus Blue requests, fax to 1-866-601-4428.
  - For BCN Advantage requests, fax to 1-800-459-8027.

### List of requirements

For a full list of requirements related to drugs covered under the medical benefit, see the [Blue Cross and BCN utilization management medical drug list for Blue Cross commercial and BCN commercial members](#). We'll update this list to reflect the changes related to these drugs.

Authorization isn't a guarantee of payment. Health care practitioners need to verify eligibility and benefits for members.

\*Clicking this link means that you're leaving the Blue Cross Blue Shield of Michigan and Blue Care Network website. While we recommend this site, we're not responsible for its content.